Stop prescribing injectable medicines containing the active ingredient Tolperisone

The Drug Administration of Vietnam (Ministry of Health) has just issued a document requesting the suspension of circulation, recall and immediate cessation of prescription nationwide of injectable drugs containing the active ingredient Tolperison, due to unwanted side effects.

Illustration photo. (Source: solarsystems-usa.info)

Deputy Director of the Drug Administration of Vietnam Nguyen Viet Hung said that the above request was made based on current pharmaceutical regulations in Vietnam; based on the conclusion of the Drug Review Council of the Ministry of Health on May 9, 2013 on recalling injectable drugs containing the active ingredient Tolperison due to the risk being higher than the benefits when using this drug.

Therefore, to ensure safety for users, the Drug Administration of Vietnam has suspended nationwide circulation and recalled all injectable drugs containing the active ingredient Tolperison.

Referring to injectable drugs containing this active ingredient, nurse Nguyen Xuan Vinh - Department of Cardiovascular and Thoracic Surgery - Viet Duc Friendship Hospital said that injectable drugs containing the active ingredient Tolperison are currently being used very commonly in many hospitals.

“The reason is that the injection contains the active ingredient Tolperison, which treats muscle diseases, degenerative spine disease, joint pain, lumbar and cervical syndromes, and treats vascular occlusions (obstructive atherosclerosis, etc.) as well as syndromes that appear on the basis of impaired neurovascular distribution (cyanosis of the extremities, difficulty walking due to episodic neurovascular disorders). In particular, the drug contains the above active ingredients to restore function after trauma and orthopedic surgery,” nurse Vinh analyzed.
To ensure strict recall, the Drug Administration of Vietnam requires importers and distributors of injectable drugs containing the active ingredient Tolperison to coordinate with drug suppliers and distributors to send recall notices to places that distribute and use injectable drugs containing the active ingredient Tolperison and recall all of the above drugs nationwide.

The above units send recall reports and recall records of injectable drugs containing the active ingredient Tolperison according to regulations to the Department of Drug Administration before July 30, 2013.

In particular, Mr. Hung noted that hospitals and clinics with beds should immediately stop prescribing and using injectable drugs containing the active ingredient Tolperison and return the drugs to distribution and supply facilities.

The Department of Health of provinces and centrally run cities and health sectors notify drug businesses and users to stop using and recall injectable drugs containing the active ingredient Tolperison.

Regarding supervision, the Drug Administration Department requests relevant authorities to inspect and supervise units implementing this notice and handle violators according to current regulations, report to the Drug Administration Department and relevant authorities./.

According to (Vietnam+) - LT